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A b o u t  H e p p
HEPP News, a forum for correctional
problem solving, targets correctional
administrators and HIV/AIDS care
providers including physicians, nurses,
outreach workers, and case managers.
Published monthly and distributed by fax,
HEPP News provides up-to-the-moment
information on HIV treatment, efficient
approaches to administering HIV treatment
in the correctional environment, national
and international news related to HIV in
prisons and jails, and changes in correc-
tional care that impact HIV treatment.
Continuing Medical Education credits are
provided by the Brown University Office of
Continuing Medical Education to physi-
cians who accurately respond to the ques-
tions on the last page of the newsletter.  
The editorial board and contributors to
HEPP News include national and regional
correctional professionals, selected on the
basis of their experience with HIV care in
the correctional setting and their familiarity
with current HIV treatment. We encourage
submissions, feedback, and correspon-
dence from our readership.  The goal of
HEPP News is to provide our readers with
reports of effective and cost-conscious HIV
care that can truly be implemented with the
correctional environment.  We hope our
newsletter achieves that goal.
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For the treatment of HIV infection, many
physicians opt to use combination antiretro-
viral therapy which is not addressed by the
FDA.
Hepp News is grateful for the primary support of
Agouron Pharmaceuticals through an unrestricted
educational grant  and the additional support of Roche
Pharmaceuticals.
If you have any problems with this fax transmission please call 888.447.1906 or e-mail us at:    ccg@ccgnetwork.com
HEPP News is sponsored by the Brown University School of Medicine Office of Continuing Medical Education and the Brown University AIDSProgram
O c t o b e r  1 9 9 9  •  V o l u m e  2 ,  I s s u e  9 Brown University School of Medicine Providence, RI 02912 
tel: 401.863.2180 • fax: 401.863.2660 • www.hivcorrections.org
ICAAC H igh l ights ,  Par t  I :  HAART Tr ia l  Reports
Joe Bick, M.D.
Chief Medical Officer
HIV Treatment
California Medical Facility, Vacaville, CA
Speaker's Bureau: Agouron, Bristol-Myers
Squibb
The 39th annual Interscience Conference on
Anti-microbial Agents in Chemotherapy (ICAAC)
was held in San Francisco September 25-29,
1999. From the correctional perspective, some of
the most relevant HIV related topics that were dis-
cussed include: longer term follow-up of some
previously reported highly active antiretroviral
(HAART) trials, genotypic and phenotypic resis-
tance testing, discontinuation of opportunistic
infection (OI) prophylaxis, further elucidation of
host factors involved in the immune response to
HIV, and troubling information regarding side
effects of HAART.
One common theme was that the most important
predictor of achieving an undetectable HIV viral
load (VL) is patient adherence to therapy. In spite
of glowing reports from some clinical trials, the
fact remains that approximately 40% of previous-
ly treatment naïve patients receiving HAART will
experience virologic failure within one year.
Nationwide, about one third of patients on > 3
agents have HIV VL >20,000.  The proportion of
patients who will maintain an HIV VL of < 400
drops precipitously when adherence falls below
95% (i.e. missing 1-2 doses per month).
Understanding that a major predictor of a
patient's adherence to therapy is trust in his or her
clinician, it is crucial to implement approaches in
correctional settings that allow effective patient
education and foster trusting relationships with
clinicians. Correctional providers should take the
time to carefully review treatment options with
their patients, since the initiation of HAART is
rarely an emergency, and the second regimen
rarely works as well as the first. 
This month's report from ICAAC will review
HAART trial reports and HIV resistence testing.
Next month's report will discuss updates con-
cerning opportunistic infection side effects and
host factors. 
Longer-term Data on Multiple Clinical Trials
Longer-term data on multiple clinical trials was
presented and demonstrated a clear role for non-
protease inhibitor (PI) containing regimens in the
initial treatment of ART naïve patients. Brief syn-
opses follow:
•  CNA 3005:  48 week data was presented
from this study which compared zidovu-
dine(AZT) / lamivudine(3TC) / indinavir(IDV)
vs. AZT/3TC/abacavir(ABC).  In terms of
achieving an HIV VL of <400, the triple nucle-
oside class sparing combination performed
as well as the PI containing regimen.  In the
subset of patients who began therapy with a
VL of >100,000, the PI containing arm was
more successful. 
•  DUPONT 006:  72 week data was present-
ed from this study comparing
AZT/3TC/efavirenz (EFV) vs AZT/3TC/IDV
vs EFV/IDV.  In an intent to treat analysis (see
glossary), the AZT/3TC/EFV arm performed
significantly better than the AZT/3TC/IDV arm
in achieving a VL of <400 and <50. Not only
did the PI sparing regimen perform better, it
was better tolerated. 
•  DUPONT 006 (AZT/3TC/EFV)
DUPONT 043 (d4T/3TC/EFV)
DUPONT 049 (ddI/d4T/EFV)
A comparison of these three PI sparing regi-
mens which each utilized 1NNRTI + 2NRTIs
revealed similar outcomes.  This information
provides further flexibiliy in terms of which
nucleoside agents to utilize in an EFV con-
taining PI sparing regimen.
•  VIRGO: 52 week data of a regimen com-
posed of once daily nevirapine (NVP) and
didanosine (ddI) with twice daily stavudine
(d4T) demonstrated sustained efficacy with
roughly 2/3 of patients having VL <50.
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•  Atlantic Study:  48 week data was presented on this study which
involved three arms.  Each included  ddI, d4t, and either IDV, NVP, or
3TC.  All three arms were similarly successful in achieving an HIV Vl
of <400.  The triple nucleoside arm of ddI/d4T/3TC was less effica-
ceous in those who started out with HIV VL of >100,000, and was also
less effective in achieving a VL of <50.
When considered together, the above studies provide strong evidence for
the efficacy of PI sparing regimens utilizing either 3 NRTIs or 2 NRTIs plus
1NNRTI in ART naïve patients. This data suggests, however, that triple
nucleoside regimens perform less well in those with baseline HIV VL's of
>100,000 (see also our Expert Opinion on intensification, by HEPP editor
Rick Altice - on page 4). Non PI containing-regimens involve fewer pills,
fewer doses, and often less side effects - all factors which can help improve
adherence.  Data also revealed that EFV/dual nucleoside regimens are as
effective as those containing PIs in reducing HIV replication in sanctuary
sites such as lymph nodes.
Dosing news:
•  "TID BID":  This study provides data that 1600 mg of saquinivir (SQV)
bid or 1200 mg SQV bid with 1250 mg bid NFV are as effective in com-
bination therapy as 1200 mg SQV tid. 
Other ART Agents
•  Adefovir:  a nucleotide reverse transcriptase inhibitor (RTI), dosed
qd. Adefovir currently has investigational new drug status, showing
0.3-0.4 log decline in HIV VL in those with prior treatment failure.
Adefovir is not active against AZT resistant virus, but activity is
enhanced in the presence of the 184 resistance mutation.  Renal toxi-
city can be significant, but may be decreased if dosing is reduced from
120 mg/d to 60 mg/d.  Additionally, probenecid may decrease nephro-
toxicity.
•  Tenofovir: (also known as PMPA pro-drug): Also a nucleotide RTI,
administered once daily.  Less toxic than adefovir, and more effica-
ceous (decrease HIV VL 1 log). Activity is enhanced by the 184 muta-
tion and not diminished by the 151 multi-drug resistance mutation.
•  T20 fusion inhibitor:  An amino acid that blocks gp41 fusion.  No
cross resistance noted with other ART, and has shown some promise
in patients with multiple drug resistant virus at doses of 50 mg subcu-
taneously bid.
•  ABT-378/ritonavir (RTV)  An investigational second generation  PI
which utilizes low doses of RTV to markedly improve pharmakokinet-
ics.  In vitro data demonstrates activity against RTV and IDV resistant
isolates.  Week 36 data from studies involving both naïve patients and
those who had failed one PI demonstrated excellent tolerability and
potency.
•  Hydroxyurea (HU):  HU functions as an inhibitor of ribonucleotide
reductase, which leads to decreased intra cellular concentrations of
nucleosides and therefore a competitive advantage for ddI.  A pooled
evaluation of 4 trials involving >500 patients, most of whom were
asymptomatic and naïve, revealed an additional 0.4-0.6 log reduction
in HIV VL when HU was included in a ddI containing regimen.  Toxicity
was limited, including fatigue, neuropathy and <1% severe anemia.
CD4 increases were blunted in HIV regimens, but CD4% were not
affected.  In conclusion, it appears that efficacy of HU has been
demonstrated in the first line treatment of asymptomatic individuals.  
Salvage Therapy
Much less hopeful information was presented on salvage regimens for
those failing multiple other treatment combinations. Follow-up data on
"Mega HAART" (>5 drugs) guided by genotypic analysis revealed
response rates (VL<400) in about 1/3 of patients over the short term. Mega
HAART is associated with a high rate of side effects and requires a very
motivated patient. Response rates to salvage therapy were related to
patient adherence, pre-treatment VL and the use of a new drug class. 
HIV Resistence Testing  
A major focus at ICAAC was the role of HIV resistance testing in clinical
practice.  In spite of significant limitations of the current methodologies, it is
clear that resistence testing will soon be considered standard of care.
Genotypic analysis attempts to identify the viral mutations known to be
most important in predicting resistance to ART.  Phenotypic analysis is
analogous to antimicrobial resistance testing, where "resistant" is general-
ly defined as ten times the IC 90 of the virus.  Both methods are expensive
and time consuming.  It is likely that over the next year, costs and turn
around times will fall, making testing more accessible.
Two studies were discussed which attributed improved patient outcomes
(as measured by HIV VL) to the use of resistance testing.  A 12-week
analysis of the GART study revealed a benefit to genotypic analysis cou-
pled with expert opinion as opposed to standard care. The latest analysis
of the VIRADEPT study demonstrated ongoing clinical benefit to the use of
resistance testing at 12 months of follow-up (See following figure).  
VIRADEPT also analyzed serum PI levels and found that they correlated
with virologic outcomes. This data raises the question of whether drug lev-
els will eventually become an important part of our treatment strategies.
There was considerable discussion concerning the substantial variability in
reliability of resistance testing from one lab to another.  Other data demon-
strated that patients who experience virologic failure to HAART are often
resistant to only one drug in their regimen.  In this setting, resistance test-
ing would help prevent the "discarding" of agents that retain efficacy.
Finally, a number of abstracts pointed out the significant baseline levels of
genotypic and phenotypic resistance in untreated (naïve) patients.  As with
tuberculosis, it may become important to know the prevalence of resistant
virus circulating in your patient population prior to selection of an initial reg-
imen.
Glossary
PI sparing stands for protease inhibitor sparing, or antiretroviral combina-
tions that do not include a protease inhibitor. 
Intent to Treat (ITT) Analysis versus  As Treated (AT) Analysis
When evaluating the results of a clinical trial, in the ITT analysis, if a patient
starts on one combination and then quits (for any reason) they are count-
ed as a treatment failure.  In the AT analysis, the data is evaluated based
upon the success of what the patient is actually taking.For example, con-
sider two different treatments. One works in 100% of the people but is so
dreadful that only 10% of patients can stay on it.  A second treatment works
in only 80% of the people, but is much more tolerable.  If the two treatments
were compared, the type of analysis used would lead to different interpre-
tations.
In the as treated analysis, the therapy that only 10% of the people could
stay on would look better because those who stayed on it all did well.  In
the intent to treat analysis, the therapy that worked  80% of the time but
was much more tolerable would be graded better.
October  1999 •  Vo lume 2 ,  I ssue 9 2v i s i t  H E P P N e w s  O n l i n e  a t  w w w . h i v c o r r e c t i o n s . o r g
ICAAC H igh l ights ,  Par t  I :  HAART Tr ia l  Reports
Continued from page 1
OC         OC       SOC     SOC
+G          -G        +G         -G
Reduction in
Viral Load
OC= optimal [PI]
SOC= suboptimal [PI]
+G=genotyping done
-G=genotyping not done
Senior Advisory Board
Joe Bick, M.D.
California Dept. of Corrections
Roderic D. Gottula, M.D.
Society for Correctional Physicians
Theodore M. Hammett, Ph.D.
Abt Associatesv
Ned E. Heltzer, R.Ph., M.S.
Prison Health Services, Inc.
Stephen Tabet, 
Univ. of Washington
Division of Infectious Disease
Seattle HIVNET
David Thomas, J.D., M.D.
Florida Dept of Corrections
Managers
Dennis Thomas
HIV Education Prison Project
Michelle Gaseau
The Corrections Connection
Layout 
Mary Sheehan
The Corrections Connection
Promotion and Distribution
Amanda Butler
Cimon Consulting Group
Editorial Associates 
Elizabeth Stubblefield
HIV Education Prison Project
Christine Mastal
The Corrections Connection
Associate Editors
Timothy P. Flanigan, M.D.
Brown University School of Medicine
David P.Paar, M.D.
University of Texas Medical Branch
Anne C. Spaulding, M.D.
Brown University School of Medicine
David A. Wohl, M.D. 
University of North Carolina
Betty Rider, M.A., M.S.
North Carolina Division of Prisons
Steve Szebenyi, M.D.
Albany Medical College
HEPP News is published twelve times
a year by the Brown University 
AIDS Program
Box G-B426 • Providence RI 02912
tel:401.863.2180
fax:401.863.1243
e-mail:heppnews@brown.edu
If you have an difficulties with this fax
transmission please call 888.447.1906
October  1999 •  Vo lume 2 ,  I ssue 9 3v i s i t  H E P P N e w s  O n l i n e  a t  w w w . h i v c o r r e c t i o n s . o r g
Dear colleagues, 
We're thrilled to announce that this issue marks the first anniversary of HEPP News. Over the past year
we've worked extremely hard to bring you HIV treatment information, news, and resources that are rele-
vant to prison and jail HIV care, written by HIV experts who work in corrections. We provide HEPP News
to you in fax format so that you can have it right at work, and we provide access to the newsletter in down-
loadable formats at www.HIVcorrections.org, where back issues are also archived. As of January 2000,
we'll be able to email the newsletter directly to you in PDF format as it rolls off the press. Furthermore,
we're working on integrating this newsletter with another resource, HIV Inside, a quarterly publication pro-
viding more basic HIV education for correctional care providers that are not yet HIV specialists (see sub-
scription forms for both resources on the last page). We certainly hope our readership is pleased with th
HIV care resources that are now available in a range of formats. 
Indeed, the year has been full of outstanding events for those of us who are involved with HIV care in cor-
rectional settings.  There's been a flurry of interest in our topic - first from the Correctional Black Cau us,
then by Donna Shalala's office (HHS). Correctional HIV care also created a stir at the National HIV
Prevention Conference in Atlanta where Ted Hammett (Abt Associates) reported that prison inmates are
five times more likely than non-inmates to have AIDS and 10 times more likely to have HIV. It's now pub-
lic knowledge that the number of HIV infected individuals we care for in correctional settings represent
almost 20% of the total number of HIV infected patients who are in treatment in the US. 
HIV in corrections is also attracting the attention of public opinion makers and policy makers. Reverend
Jesse Jackson joined forces with public health officials and correctional experts at a meeting held in
Chicago (the October 2-3, 1999 Public Health / Corrections Collaborations meeting - a second meeting
on this topic will be held at the NCCHC conference in November, see Dates for more information). He
pointed out that people living with HIV are "all under one big tent," whether they're getting their care in the
prison or in the community" and urged policy makers to focus on linking health care and disease preven-
tion in correctional facilities with health care "outside" corrections.  He urged greater collaboration
between corrections and public health, stating that policy makers must address the epidemic of HIV in
minority communities or become "dream busters."
Another event that received a great deal of press coverage was the conference on Clinical Trials in
Correctional Settings sponsored by HIV Education/Prison Project (HEPP at Brown University), the Yale
HIV in Prison Project, and the Center for Interdisciplinary Research on AIDS (CIRA, Yale University).
Correctional HIV experts, lawyers, prisoner advocates and ethicists gathered in Providence to discuss
current HIV/AIDS studies that are being conducted in correctional settings and to develop more detailed
guidelines for the conduct of such trials than currently exist. A list of the conference participants is pro-
vided on our website, and a full report on the conference will be published in HEPP News, next month.
This anniversary issue of HEPP News brings you an update on HIV treatment from the Interscience
Conference on Anti-microbial Agents in Chemotherapy (ICAAC) and an expert opinion on intensification.
Intensification is a newer approach to HIV management made possible by viral load monitoring. This
approach, as outlined by HEPP editor Rick Altice may permit correctional HIV care providers to avoid hav-
ing to salvage patients with new regimens of HAART until absolutely necessary. A wise HIV care provider
can thereby "save" ART options for the future, and avoid exposing the patient to frequent medication
changes which can be expensive and may be associated with additional side effects. 
After reading this issue of HEPP News, readers should be able to describe the benefits and drawbacks
of intensification versus salvage therapy, list possible drug interactions with individual antiretrovirals, and
understand the latest updates on HAART trials HIV resistance testing.
Thank you for your continued support of HEPP News.  We look forward to hearing from you!
Sincerely,
Anne De Groot, MD
HEPP Editor
L E T T E R F R O M T H E E D I T O R
WEBSITES
Quick Reference Guide to Antiretrovirals and
New Antoretrovirals
http://hiv.medscape.com/Medscape/HIV/Treatm
entUpdate/1998/tu01/public/toc-eng.tu01.html
University of Penn. AIDS Service Websites
http://www.med.upenn.edu/~pennactu/service
sites/
HIV and Its Treatment: 
What You Should Know
http://hivatis.org/atisnew.html
This consumer brochure includes information
from the Guidelines for the Use of Antiretroviral
Agents in HIV-Infected Adults and Adolescents
and uses a question and answer format to make
the information easier to understand by people
without a technical background. It also includes
a section on adherence to treatment plans.
The Journal of the American Medical
Association HIV/AIDS Information Center
Antiretroviral Therapy for HIV Infection Page
http://www.ama-assn.org/special/hiv/treatmnt/
guide/guidtrt.htm
HEPP News
http://www.hivcorrections.org
The Corrections Connection
http://www.corrections.com
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Frederick L. Altice, M.D.
Director
HIV in Prisons Project, Yale University AIDS Program
Speaker's Bureau: BMS, DuPont,Glaxo Wellcome, Agouron, 
Abbott, Roche, Merck
Grant Research Support: Abbott, Roche
Consultant: BMS, DuPont, Glaxo Wellcome, Agouron
HIV treatment is getting more complex as treatment options multi-
ply and information on viral resistance becomes more readily avail-
able. Correctional HIV providers need to learn to consider intensifi-
cation as an option for their patients if their initial HIV regimen
appears to be failing. This article will give you an "inside view" of this
new approach to HIV management. 
Current guidelines for the use of antiretroviral therapy for the man-
agement of HIV disease include the use of at least three antiretro-
virals for initial therapy.  Across many studies of individuals receiv-
ing recommended combination therapy, the proportion achieving a
virologic response of an HIV-1 RNA level less than  500 copies is
around 70%-80%. However, the proportion of patients achieving the
more desirable viral load of less than 50 copies is only approxi-
mately 40%-50%.  
Patients who fail to achieve a non-detectable viral load (less than 50
copies) are more likely to have virologic progression and develop
resistance to antiretroviral medications than those who do not
achieve virologic success. Low level replication is bound to lead to
resistance. Therefore, though a virologic failure may not immedi-
ately lead to immunologic failure (lower CD4 T cell counts), the
implication of low level viral replication in the presence of antiretro-
viral therapy for future antiretroviral options could be serious for the
patient and even more expensive, in the long run. 
Future options for a patient experiencing viral replication in the face
of HAART may be difficult to tolerate and to design, especially if a
second (or third) regimen requires five, six or seven antiretrovirals
to overcome multi-drug resistant strains. Thus, it remains a major
priority to initiate appropriate and potent antiretroviral therapy with
the initial regimen and monitor response to the regimen very close-
ly. The mantra of HIV therapy has now been modified to: start early,
start hard, and start smart.
Predictors of Virological Failure
Clinicians who understand the causes of virological failure can
make informed decisions about how to prevent it.   Four major fac-
tors predict virological failure:  
• the presence of HIV-1 resistant strains to individual or multiple
antiretrovirals at the time of initiation of therapy (baseline resis-
tance); 
• HIV-1 RNA more than 100,000 copies/mL at the time of initia-
tion (baseline high viral load);
• CD4 less than 200 cells/mL (baseline immunological compro-
mise); and 
• non-adherence with antiretroviral therapy.  
Possible approaches to the management of each of these causes
of treatment failure are discussed in the next few paragraphs.
Baseline HIV Resistance
Prevalence of baseline resistance to one or more antiretrovirals has
been reported at previous meetings (see HEPP News report on the
6th Retrovirus meeting, March 1999, archived at
http://www.HIVcorrections.org). As a result, many clinicians are
choosing to obtain genotypic or phenotypic resistance testing
before initiating therapy. Even though this approach is not yet con-
sidered to be standard clinical practice, the rationale is that if base-
line resistance is detected, an alternative antiretroviral regimen
could be selected to assure that all of the agents in the initial regi-
men will have an effect on the virus. If, for example, an individual
demonstrated resistance to one of the NRTIs at baseline, selecting
an alternate NRTI may put more effective pressure on the virus and
improved response to treatment.
If, in contrast, an individual were not known to be resistant to one
antiretroviral, and was started on that agent along with two others in
the initial regimen, the combination would be equivalent to treat-
ment with only two agents, rather than three, and would be more
likely lead to treatment failure and the development of multi-drug
resistance. These two scenarios are described in Figure 1 below.
Note the divergence in the reduction of HIV-1 RNA levels between
two patients. At baseline, one patient is infected with a genotypic
wild-type strain (non resistant)  and the other patient is infected with
a strain that has resistance to one nucleoside RTI (resulting in a reg-
imen that contains only two active agents out of the three that were
prescribed). In this setting, as illustrated, incomplete viral suppres-
sion results in the later emergence of new mutations, resulting in an
increase in HIV-1 RNA levels.
Unfortunately, existing HIV genotypic assays are not able to
evalaute all quasi-species of HIV in each patient. Thus, the patient
may be infected with resistant quasi species that are not detected
by the test. Furthermore, the selective pressure of any initial regi-
men may permit the selection of resistant quasi-species soon after
initiation. Patients who develop resistance early are likely to have
clinical indicators of their failing regimen soon after therapy is initi-
ated.  A vigilant HIV provider would be able to detect this failure
early on, and would then modify therapy before multi-drug resistant
strains develop.
Baseline HIV-1 RNA More Than 100,000 
The major reason patients with high viral loads do not achieve com-
plete viral suppression is that many three-drug antiretroviral combi-
nations may not be potent enough to reduce the burden of virus in
the body. Simply put,  the larger the difference between baseline
viral load and non-detectable viral load, the more potent the anti-
retroviral combination must be in order to suppress the virus.
E x p e r t  O p i n i o n
Modifying HAART: Strategies for Avoiding Salvage Therapy for HIV
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For example, a patient with a baseline HIV-1 RNA level of 500,000
copies/mL (log = 5.7) would have to decrease their viral load by
more than log 4.0 (more than 10,000 fold) to achieve a viral load of
less than 50 copies/mL. Unfortunately, most three-drug regimens
achieve a mean of 2.5 to 3.0 log reductions. The range for viral load
reduction is obviously quite variable. In addition, other co-factors
such as baseline CD4 lymphocyte count and baseline resistance
contribute to the magnitude in viral load reduction.
Baseline CD4  Less Than 200
CD4 lymphocyte responses remain a critical component in the host's
response to controlling HIV replication. When this system of defense
is compromised, lymphocyte killing of HIV is diminished, even in the
setting of potent antiretroviral therapy. Patients with low CD4 lym-
phocyte counts are less likely to have an effective cell-mediated
response to HIV compared to those individuals with higher CD4
counts. Therefore, it is no surprise that individuals with a low CD4
lymphocyte count commonly have an extremely high HIV-1 RNA
level, though the correlation is not perfect. Thus, low CD4 and high
HIV-1 RNA, can each contribute to failing standard combination
therapy.  
Preventing Treatment Failure
Four-drug initial therapy is one possible intervention for patients who
have high initial viral loads or low initial CD4 T cell counts. However,
patients with advanced disease are also more likely to experience
adverse side effects from antiretroviral therapy compared to those
with less-advanced disease. Thus, many clinicians may wish to
avoid the use of four (or more) antiretrovirals when initiating therapy,
realizing that they may not achieve virologic success. The question
is, then, what are the options for better treatment in this setting?
Intensification vs. Salvage 
Intensification refers to the strategy of adding an additional agent or
agents when the initial regimen appears to need a 'boost' to improve
its effectiveness. Intensification is implemented when the initial reg-
imen is continuing to reduce HIV-1 RNA levels (i.e. no increase in
HIV-1 RNA), but  the regimen does not appear to be likely to achieve
virological success by the end of six months (the time when all ini-
tial antiretroviral regimens should achieve maximal HIV-1 suppres-
sion). In this setting, intensification may be used, because HIV-1 lev-
els are continuing to decline, and the development of resistant
strains is unlikely.  
Salvage therapy, on the other hand, is used when an initial anti-
retroviral combination has achieved an initial response (with or with-
out achieving maximum virological suppression), followed by an
increase in HIV-1 RNA levels. Of course, the astute clinician will
want to rule out non-adherence to the medications before modifying
the regimen. In the face of adherence, an increase in HIV-1 levels
suggests the emergence of antiretroviral resistant strains. 
Thus, intensification allows the clinician to add a new medication to
a regimen that is succeeding but needs a little help while salvage
implements a new or markedly modified regimen  in the setting of
developing resistance. The clinician must carefully exclude non-
adherence and early resistance as other possible explanations for
the viral load increase, and only then intensify therapy.
Early Signs of Treatment Failure
• Three early predictors of failing an initial antiretroviral com-
bination have been identified: HIV-1 RNA level =1,000 at
Week four; 
• HIV-1 RNA level = 400 copies at Week twelve; and 
• HIV-1 RNA = 50 copies at Week 24. 
Viral Load Monitoring
To consider intensification therapy in a correctional setting, an HIV
specialist must have access to regular viral load testing. The costs
for viral load testing are infinitely less than the cost of changing a fail-
ing regimen. In order to assess the efficacy of therapy, viral load
determinations should be obtained at least four, twelve, and twenty-
four weeks after an antiretroviral combination is initiated. If the HIV
cli ician is concerned that a patient may fail, monitoring viral load
frequently (i.e. monthly) may be necessary. Increases in viral load
are an indicator that intervention may be required.
Figure 2 below schematically illustrates the difference between
patients who initiate unsuccessful combination antiretroviral therapy
and whose regimens are either intensified or salvaged at Week 24.  
Both patients depicted in this graph have a baseline HIV-1 RNA of
r und  350,000 copies/mL (high risk for virologic failure) and
respond with an initial brisk reduction in HIV-1 RNA levels. 
Earlier Salvage
Th  patient with the solid line had a viral load reduction of about  2.5
log by Week 12 (but only to a level of around 2,000 copies) where
the viral load level initially stabilizes. By Week 24, however, the HIV-
1 RNA level has increased by about 1.0 log in the setting of perfect
adherence. Pathophysiologically, from Week 12 through Week 20,
viral replication of the wild type was maximally suppressed and the
development of resistant strains had begun. This lead to emergence
of resistant strains by Week 24 when an entirely new antiretroviral
combination (salvage therapy) was initiated with a prompt reduction
in HIV-1 RNA levels.  
Even though salvage was clearly indicated at this point, the patient
might have benefited if his regimen had been modified earlier rather
th n waiting until week 24 to completely replace the regimen. The
success of salvage therapy is moderated by how early therapy is
cha ged after viral replication has increased. The best success
when using a salvage regimen is a change in therapy when the viral
load remains low (theoretically when there are less genotypic muta-
tions conferring resistance).
Continued on page 7
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Continued from page 4
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HEPPigram A feature of HEPPNews providing concise solutions to correctional HIV-related problems.
Medications-Related
• Inform patient, anticipate, and treat side effects
• Simplify food requirements
• Avoid adverse drug interactions (see HIV-101)
• If possible, reduce dose frequency and number of pills
• Adapt schedule to patient's schedule
Doctor Related
• Establish trust
• Either serve as educator, source of information, ongoing support and monitoring, or provide access to a trusted individual such as a nurse
case manager who can perform the above.
• Provide access between visits for questions
• Monitor ongoing adherence; intensify management in periods of low adherence (i.e. more frequent visits and deployment of other team
members.  In systems which use directly observed therapy (DOT) or modified DOT, check the medication logs to verify.)
• Consider impact of new diagnoses on adherence, e.g. depression, liver disease, wasting, recurrent chemical dependency, and include
adherence intervention in management
• Schedule frequent follow up visits soon after initiating or changing treatment plan
Patient Related
• Ask patient to keep a 1-2 week diary of activities before starting therapy to identify key facilitators or barriers to adherence.
• Describe and agree on a treatment plan
• Check that the patient understands the plan
• Ask the patient to adhere to the plan
• Take time, multiple encounters to educate and explain goals of therapy and need for adherence
• Develop concrete plan for specific regimen, relation to meals, daily schedule, side effects
• Provide written schedule and pictures of medications and other medical aids to adherence 
• All HIV infected persons should be screened, and if indicated, should be treated for co-morbid mental illnesses
System Related
• Confidentiality is essential within the units of the correctional system, with special attention to the patient's safety and security 
• Develop adherence support groups, or add adherence issue to regular agenda of support groups
• Continuous healthcare intervention should be provided, including follow up without a break in care upon transfer or discharge from a cor-
rectional facility
• Timely and appropriate access/accommodation to care is needed that is comparable to that available in the community
• Establish an HIV care team
Strategies to Improve Adherence
Adapted from Altice FL, Buitrago MI. (1998). Adherence to antiretroviral therapy in correctional settings.  J Correctional Health Care. 5:2. 179-200, as
well as The Living Document: Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, May 5, 1999, available at
www.hivatis.org 
S A V E T H E D A T E S
The Eighth Annual UCLA AIDS
Institute Scientific Symposium
"Global Challenges"
November 19, 1999 
The Anderson School at UCLA,
Korn Convocation Hall
Los Angeles, CA
Keynote Speaker: Dr. Helene
Gayle, Director of CDC's National
Center for HIV, STD and TB
Prevention.  For further information
call 310.794.5335
http://www.medsch.ucla.edu/aidsin
st/about/Conferences.htm
6th National AIDS Treatment
Forum
December 11-14, 1999
Miami, Florida
The purpose of the conference is to
develop HIV treatment educators
and case managers. Sponsored by
NATAF. 
Contact: National Minority AIDS
Council at 202.483.NMAC (6622).
Register by November 15, 1999
Retroconference 2000 - 7th
Conference 
January 30-February 2, 2000 
San Francisco, CA
Registration opens for abstract
authors: November 12, 1999
Registration opens for other
researchers and clinicians:
November 30, 1999
Late breaker abstract deadline:
January 5, 2000
The Call for Abstracts will be post-
ed at the following site: 
http://www.retroconference.org/
10th Annual Clinical Care
Options for HIV Symposium
May 4-7, 2000
Hyatt Gainey Ranch, 
Scottsdale, Arizona
http://hiv.medscape.com/Medscape
/public/symposia/AIDS2000/form
symp2000.html
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Modifying HAART: Strategies for Avoiding Salvage Therapy for HIV
Appropriate Intensification
The patient depicted by the dashed line is an example of an anti-
retroviral intensification strategy.  Similar to the patient with the solid
line, the baseline viral load is around 350,000 copies/mL and rapid-
ly decreases soon after initiation of a three-drug antiretroviral com-
bination. From Week 12 to Week 24, the HIV-1 RNA is continuing
to decrease, albeit slowly.  This is in contradistinction to the other
patient.  Here, the patient had not achieved a non-detectable viral
load by Week 24 and  the viral load had not risen, therefore a fourth
antiretroviral agent could be added to the regimen to maximize viral
suppression.  Note that in this setting a single drug is being added
to a succeeding regimen, not a failing regimen. When a regimen is
failing, the appropriate intervention is salvage therapy instead of
intensification. 
How to Intensify?
Studies of antiretroviral intensification are currently underway.
Unfortunately, no clinical trials have been performed as yet that indi-
cate which antiretrovirals are appropriate for intensification of thera-
py. The following recommendations are issued, therefore, with the
caveat: intensification therapy is currently based on cientific princi-
ples and not on health outcomes research.
The table below lists potential intensification options for patients ini-
tiating antiretroviral therapy.  A decision to intensify should be made
based on viral load at one of the three time points:  week 4; week
12; or week 24.
It is important to note that intensification never applies to two drug
regimens, which are only recommended in highly controlled circum-
stances. Therefore intensification should NEVER include starting
with two antiretrovirals and adding a third after six months when viral
suppression is not achieved, as two drug regimens have all proven
to be inferior to three-drug combinations.  
Summary and Key Points
Optimal initial antiretroviral therapy includes the use of at least three
potent antiretrovirals, a regimen that has been shown to allow a
majority of patients to achieve and sustain a non-detectable viral
load. For those patients who do not reach this goal, there are sev-
ral clinical predictors which can guide clinicians to optimize thera-
py before virological failure occurs and less-optimal salvage thera-
py must be initiated. One such strategy to avoid salvage therapy
includes antiretroviral intensification. This approach may avoid the
development of antiretroviral resistance, and the associated toxici-
ties of four or more antiretrovirals during initial therapy and may ulti-
mately be more cost-effective than salvage therapy regimens. The
s rategy is unproven as of yet, although it is gaining favor in com-
munity HIV practices and holds promise for the future. Successful
implementation of intensification strategies is dependent upon the
availability of frequent viral load testing. Appropriate use of intensi-
fication may, in the long run, reduce correctional HIV costs. While
we anticipate more information on outcomes studies, we may judi-
ciously implement this approach in our management of correctional
HIV patients.
SUBSCRIBE TO HEPP NEWS
FAX TO 800.671.1754 FOR ANY OF THE FOLLOWING: (please print clearly or type)
____  Yes, I would like to add/update/correct (circle one) my contact information for my complimentary subscription of HEPPNews fax newsletter.
____  Yes, I would like to sign up the following colleague to receive a complimentary subscription of HEPPNews fax newsletter.
____  Yes, I would like to order the following back issues (please include volume/issue/date).
____  Yes, I would like my HEPPNews to be delivered as an attached PDFfile in an e-mail (rather than have a fax).
NAME: __________________________________________________________________________________________
TITLE: __________________________________________________ E-MAIL ADDRESS: ________________________
FACILITY:________________________________________________ (Optional) # of Inmates:______________________
ADDRESS: ________________________________________________________________________________________
FAX:____________________________________________________ PHONE: __________________________________
SIGNATURE: ____________________________________________ DATE:____________________________________
Initial Antiretroviral Combination Intensification Antiretroviral
3 NRTIs + PI or + NNRTI
2 NRTIs + NNRTI + NRTI or + PI
2 NRTIs + PI + NRTI or + NNRTI
3 NRTIs* + Hydroxyurea (HU)
2 NRTIs* + NNRTI + Hydroxyurea (HU)
2 NRTIs* + PI + Hydroxyurea (HU)
* Since HU works with DDI, One NRTI should be didanosine if hydroxyurea is considered.
Continued from page 5
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Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
Table 1: Drugs that Should Not be Used With Antiretrovirals
(Adapted from HIVATIS webpage:  www.thebody.com/hivatis/agents/agents01.html)
Drug
Category Indinavir Ritonavir Saquinavir Nelfinavir Amprenavir Nevirapine Delavirdine Efavirenz
Analgesics None Mepiridine,
Piroxicam,
Propoxyphene
None None None None None None
Ca++
Channel
Blocker
None Bepridil None None None None None None
Cardiac None Amioderone,
Encainide,
Flecainide,
Propafenone,
Quinidine
None None None None None None
Lipid
Lowering
Agents
Simvastatin,
Lovastatin
Simvastatin,
Lovastatin
Simvastatin,
Lovastatin
Simvastatin,
Lovastatin
Simvastatin,
Lovastatin
None Simvastatin,
Lovastatin
None
Anti-
mycobacterial
Rifampin None Rifampin,
Rifabutin
Rifampin Rifampin None Rifampin,
Rifabutin
None
Antihistamine Astemizole,
Terfenadine
Astemizole,
Terfenadine
Astemizole,
Terfenadine
Astemizole,
Terfenadine
Astemizole,
Terfenadine
None Astemizole,
Terfenadine
Astemizole,
Terfenadine
Gastro-
intestinal
Drugs
Cisapride Cisapride Cisapride Cisapride Cisapride None Cisapride,
H-2 Blockers,
Proton pump
Inhibitors
Cisapride
Anti-
depressant
None Bupropion None None None None None None
Neuroleptic None Clozapine,
Pimozide
None None None None None None
Psychotropic Midazolam,
Triazolam
Clorazepate,
Diazepam,
Estazolam,
Flurazepam,
Midazolam,
Triazolam,
Zolpidem
Midazolam,
Triazolam
Midazolam,
Triazolam
Midazolam,
Triazolam
None Midazolam,
Triazolam
Midazolam,
Triazolam
Ergot
Alkaloids
(vaso-
constrictor)
Dihydro-
ergotamine
(D.H.E. 45)
ergotamine*
* (various
forms)
Dihydro-
ergotamine
(D.H.E. 45)
ergotamine*
* (various
forms)
Dihydro-
ergotamine
(D.H.E. 45)
ergotamine*
* (various
forms)
Dihydro-
ergotamine
(D.H.E. 45)
ergotamine*
* (various
forms)
Dihydro-
ergotamine
(D.H.E. 45)
ergotamine**
(various forms)
None Dihydro-
ergotamine
(D.H.E. 45)
ergotamine*
* (various
forms)
Dihydro-
ergotamine
(D.H.E. 45)
ergotamine*
* (various
forms)
HIV/AIDS Behind Bars, 1999: Public Health/Corrections Collaborations
Pre-Conference Colloquium on Saturday, November 6 from 1pm to 5pm
23rd National Conference on Correctional Health Care, Fort Lauderdale, FL
The Conference:
The goal of this year's colloquium is to describe the rationale for engaging in collaborations between public health and cor-
rectional health. Representatives of the CDC and HRSA will discuss  funding mechanisms for this type of collaboration.
Examples of successful projects will be presented.  Register with the registration for the NCCHC conference. CME avail-
able. 
Travel Fellowships:
Travel fellowships are for persons wishing to learn more about how to improve HIV diagnosis, management and continu-
ity of care by creating collaborations with public health agencies.  First priority will go to persons who are not currently
involved in public health/corrections collaborations but would like to learn more about such opportunities.  
For more information, contact Matthew Stark at: tel: 401.863.2180 or fax: 401.863.1243 or e-mail: heppnews@brown.edu 
For more information on the 23rd NCCHC conference, call 773.880.1460 or go to http://www.ncchc.org 
* The contraindicated drugs listed are based on theoretical considerations.  Thus, drugs with low therapeutic indicies yet with suspect-
ed major metabolic contribution from cytochrome P450 3A, CYP2D6, or unknown pathways are included in this table.  Actual
interactions may or may not occur in patients.
** This is likely a class effect.
Suggested Alternatives: 
Simvastatin, Lovastatin, Atorvastatin, Pravastatin, Fluvastatin Cervicastatin (alternatives should be used with caution)
Rifabutin: Clarithromycin, Azithromycin, (MAI Prophylaxis); Clarithromycin, ethambutol (MAI Treatment) 
Astemizole, Terfenadine:  Loratidine
Midazolan, Triazolam:  Temazepam, Lorazepam
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Subscribe to HIV Inside
A new quarterly newsletter addressing HIV-management issues specific to correctional care.
If you are interested in receiving this free publication, please fill out the form below.  In addition to receiving HIV Inside, this con-
tact information will be entered into an HIV-management database, allowing additional education materials to be forwarded.
Name________________________________________________________________________________________
Title ________________________________________________________________________________________
Agency/Facility________________________________________________________________________________
Address________________________________________________________________________
City ______________________________________________ State ______________________ Zip __________
Phone ____________________________________________ Fax ______________________________________
Fax back to Brendan Maney at World Health CME at 212.481.8534
CDC Announces $7 Million for HIV and STD
Prevention in Prisons 
As correctional health officials met in Chicago
last month to create guidelines to curb the HIV
infection rate among prison inmates, the CDC
announced a $7 million grant to battle AIDS,
STDs and substance abuse among minority
prisoners in seven states, which together house
83% of the nation's inmates.  Each state --
California, Florida, Georgia, Illinois,
Massachusetts, New Jersey and New York -
will receive between $900,000 and $1.1 million.
The funding is part of the $39 million the
Congressional Black Caucus obtained to
address "a public health emergency" among
minorities, as reflected in the following statis-
tics: one out of four black men passes through
the correctional system where the HIV infection
rate is 5% and AIDS has become the leading
cause of death for black men ages 25-44.  Dr.
Helene Gayle, director of the CDC's National
Center for HIV, STD and TB Prevention said,
"Prison and jails provide a critical opportunity to
provide lifesaving HIV prevention services to a
population that might otherwise be missed.
Many of these individuals pass through these
facilities only briefly before returning to the com-
munity.  If we fail them,we fail our communities."
(Associated Press, 10/4).
NIJ/BJS Study Provides New Numbers for a
Familiar Problem: High AIDS Rates in U.S.
Prisons  
Prison inmates are 5-10 times more likely than
non-inmates to have AIDS or HIV, indicating an
AIDS prevalence rate 5 times higher than the
total population, and an HIV prevalence rate 8-
10 times higher than the total population. A
study presented at the National HIV Prevention
Conference (Atlanta, GA, August 29-
September 1) estimated that 39,000 people, or
approximately 17 percent of the 229,000 peo-
ple with AIDS in 1996, had been released from
a correctional facility that year. The percent-
ages were even higher for HIV infection, hepati-
tis C and tuberculosis.
Testing and treating persons passing through
correctional systems could greatly reduce
HIV/AIDS transmission within the community. A
survey conducted for the CDC in 1996 and
1997 found that only 10 percent of state and
federal prison systems and only 5 percent of
city and county jail systems offered compre-
hensive HIV prevention programs for inmates.
(Hammett T, Maruschak L. 1996-1996 Update:
HIV/AIDS, STDS, and TB in Correctional
Facilities. USDOJ/OJP/ NIJ.  NCJ 176344.  July
1999.)
Updated Antiretroviral HIV Drug Approvals
a d Pediatric Labeling Information
As of April 16, 1999 there are 16 drug products
(14 drug substances) approved by the Food
and Drug Administration (FDA) for the treat-
ment of HIV infection. Eight drug products have
pediatric information in the approved product
labeling. The reason for the difference in num-
bers is two of the products are related to previ-
ously approved products. Combivir is a combi-
nation formulation of two previously approved
products, zidovudine and lamivudine.
Fortovase is a new formulation for saquinavir.
http://www.fda.gov/oashi/aids/pedlbl.html
Outreach for HIV Coaxes Difficult Clients
into Drug Treatment 
People at risk for HIV/AIDS because of their
drug use behaviors can be successfully
engaged in substance abuse treatment pro-
grams through carefully designed public health
outreach efforts.  A special  issue of the journal,
Evaluation and Program Planningreported this
key finding from demonstration projects sup-
ported by the Substance Abuse and Mental
H alth Services Administration's (SAMHSA)
Center for Substance Abuse Treatment
(CSAT). The results of the study indicate that
hard-to-reach populations are more likely to
enter treatment for substance abuse through
pa ticipation in HIV outreach programs than
w uld clients recruited specifically for treat-
ment. (Evaluation and Program Planning,
September 16, 1999; special issue.)
Study Indicates Feasible STD Testing for
Women Entering Correctional Facilities 
According to a study published in the CDC’s
Morbidity and Mortality Weekly Report, r utine-
ly testing women for chlamydia and gonorrhea
infections as they enter corrections facilities is
"feasible" and would increase the number of
women undergoing treatment, as a high per-
c ntage of women in corrections facilities who
have STDs go undiagnosed.  The entire article
is available at: http://www2.cdc.gov/mmwr/
HIV-1 Drug Resistance in Newly Infected
Individuals
A September article in JAMA reported that
16.3% of 67 newly infected patients had a vari-
ent of HIV-1 that was resistant to any antiretro-
viral drug.  Twenty-seven percent were at least
threefold resistant to at least one antiretroviral
drug.  These findings indicate the need to
increase resistance testing amoung patients
infected with HIV-1.  Further research is neces-
sary to examine both the genotype and pheno-
type of transmitted viruses. (Boden et al. JAMA
9/22/99-09/29/99; 282(12): 1135).
Good News: Perinatal HIV/AIDS Trend in the
US
The CDC reported that the decline in perinatal
AIDS incidence and the increase in perinatal
zidovudine use indicate that there has been
success in implementing PHS guidelines.
Cases of perinatal AIDS peaked in 1992 and
then dropped 67 percent through 1997
(Lindegren, M et al. JAMA 8/11/99; Vol. 282,
No. 6, P. 531).  Two other recent reports also
address perinatal transmission: L Mofenson, et
al. NEJM 341(6):385-93 (1999); and P Garcia,
et al. NEJM 341(6):394-402 (1999). 
Single Dose Prophylaxis Reduces Perinatal
HIV Transmission
American and Ugandan researchers found that
a single $4 dose of nevirapine cuts transmis-
sion nearly in half, surpassing the current ther-
py of choice, a short and expensive course of
AZT.  In the Uganda study, four months after
birth, 13% of the infants receiving nevirapine
tested positive for HIV, compared with 25% of
infants receiving AZT. This simpler intervention
might prevent up to 400,000 new infections
annually in developing countries. While the
study does show promise, further study is
needed before the treatment is introduced on a
greater scale (New York Times, 7/15/99).
News Flashes 
Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through
November 30, 1999.  The estimated time for completion of this activity is one hour and there is no fee for participation in this activity.
1. A decision to intensify antiretrovirals should be based on
viral load taken at:
a) week 4, week 8, week 16
b) week 3, week 9, week 12
c) week 4, week 10, week 18
d) week 4, week 12, week 24
2. Which of these two cases should be treated with salvage
therapy?
a) Case A b) Case B c) Neither; each should be
intensified, not salvaged.
3. Indicate which of the following statements are true:
a) Clinical Trials of antiretroviral intensification have
shown clinicians which antiretrovirals are appropriate
for intensification.
b) The cost for regular viral load testing is infinitely
less than the cost of changing a false regimen.
c) Multiple encounters with the clinician do not direct-
ly improve a patient's adherence to ART.
d) Improved patient outcomes cannot be traced to the
use of resistance testing.
4. Indicate which of the following statements are false:
a) Intensification can be applied to both three-drug
and two-drug regimens.
b) One study has shown that HU taken with a ddI-
containing regimen may reduce HIV viral load by an
additional 0.4-0.6 log.
c) T20 fusion inhibitor has shown cross resistance
with other ART
5. Which of the statements below accurately describe a new
finding about the following regimen?  1600mg of SQV bid or
1200mg SQV with 1250 mg NFV bid:
a) This regimen is cross resistant with other ART
b) This regimen is as effective in combination therapy
as 1200mg SQV tid.
c) This regimen may reduce HIV viral load by an
additional 0.8 to 1.2 logs.
d) This regimen is more effective in combination ther-
apy than 1200 mg SQV tid.
BROWN UNIVERSITY SCHOOL OF MEDICINE • OFFICE OF CONTINUING MEDICAL EDUCATION • BOX G-A2 • PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME)t  sponsor contin-
uing medical education activities for physicians.  This activity has been planned and implemented in accordance with the Essentials and Standards
of the ACCME.
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, recommenda-
tions and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the
Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
main article 5  4  3  2  1   5  4  3  2  1   
secondary 5  4  3  2  1   5  4  3  2  1   
article
HEPPigram 5  4  3  2  1   5  4  3  2  1   
updates 5  4  3  2  1   5  4  3  2  1   
save the date 5  4  3  2  1   5  4  3  2  1   
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPPNews be made more useful to you?
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 Baseline HIV-1 RNA Week 12 HIV-1 RNA Week 24 HIV-1 RNA
Case A 350, 000 copies/mL 2.5 log reduction 1.0 log increase
Case B 350, 000 copies/mL 2.5 log reduction additional 0.1 log
reduction
